Advertisment

Revolutionary Antibody-Drug Conjugate MIRV Shows Promising Results in Treating Ovarian Cancer

author-image
Zara Nwosu
New Update
NULL

Revolutionary Antibody-Drug Conjugate MIRV Shows Promising Results in Treating Ovarian Cancer

Advertisment

Ovarian cancer is a significant health concern for women globally, and the search for more effective treatments is ongoing. In a breakthrough study, researchers have found that a first-in-class antibody-drug conjugate, mirvetuximab soravtansine-gynx (MIRV), shows significant benefits over chemotherapy in patients with high folate receptor α (FRα)-positive ovarian cancer. The study, published in the New England Journal of Medicine, was funded by ImmunoGen, the developer of MIRV.

Advertisment

Key Findings of the Study

The phase 3 trial was conducted to compare the efficacy and safety of MIRV with the investigator's choice of chemotherapy in treating platinum-resistant, high-grade serous ovarian cancer. The trial involved 453 participants, with 227 assigned to the MIRV group and 226 to the chemotherapy group. The participants had previously received one to three lines of therapy and had high FRα tumor expression.

The results were encouraging: MIRV demonstrated a longer progression-free survival, higher objective response rate, and significantly longer overall survival compared to chemotherapy. Specifically, the median progression-free survival was 5.62 months with MIRV, compared to 3.98 months with chemotherapy. The objective response occurred in 42.3% of the participants in the MIRV group and in 15.9% of those in the chemotherapy group. Overall survival was also significantly longer with MIRV, with a median of 16.46 months, compared to 12.75 months with chemotherapy.

Advertisment

Less Adverse Events with MIRV

Importantly, MIRV was not only more effective but also safer than chemotherapy. Fewer adverse events of grade 3 or higher, serious adverse events of any grade, and events leading to discontinuation occurred with MIRV than with chemotherapy during the treatment period. Specifically, 41.7% of the participants in the MIRV group experienced adverse events of grade 3 or higher, compared to 54.1% in the chemotherapy group. Serious adverse events of any grade occurred in 23.9% of the MIRV group, compared to 32.9% in the chemotherapy group.

Implications of the Study

Advertisment

The study's findings suggest that MIRV could be a game-changer in the treatment of platinum-resistant, high-grade serous ovarian cancer. By targeting FRα, MIRV appears to be capable of inducing responses and improving survival in patients with this type of cancer, offering hope and a potential new treatment option for patients who have been resistant to platinum-based chemotherapy.

Next Steps and FDA Review

Following these promising results, the FDA has granted priority review to the supplemental biologics license application for MIRV. The application seeks to convert the accelerated approval of MIRV for patients with FRα-positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have previously received one to three lines of systemic treatment to full approval.

In conclusion, MIRV has demonstrated a significant benefit over chemotherapy in treating ovarian cancer, offering potential hope for patients. The treatment has shown to prolong survival, increase response rates, and result in fewer adverse events, making it a promising option for those with platinum-resistant ovarian cancer.

Advertisment
Chat with Dr. Medriva !